Tindamax
(Tinidazole)Phase 2Small molecule
Tindamax is one of 82 small molecule programs targeting Hysterectomy. It is currently in Phase 2.
3
Indications
17
Total Trials
2
Active Trials
81
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
49 competitors in Hysterectomy
#DrugCompanyPhaseTrials
1Toradol
RocheApproved
Golytely
BayerApproved
Medrol
PfizerApproved
Atarax
PfizerApproved
Marcaine
IInnocoll
Approved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Oxycontin
PProtega
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Neurontin
VViatris Specialty LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Helicobacter Pylori4 trials
Show 1 more trial
Bacterial Vaginosis3 trials
Antibiotics1 trial
7 more indications
First-line Treatment1 trial
Lymphoma1 trial
Urethritis1 trial
Phase II Randomized, Placebo-Controlled Double-Blind 4-Arm Trial for the Treatment of Non-Gonococcal Urethritis (NGU): Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00322465·305 enrolled
Helicobacter Pylori Infection1 trial
Comparison of Metronidazole- and Tinidazole-Based Bismuth Quadruple Regimens for Helicobacter Pylori Eradication
Not yet recruiting·UUniversity of Medicine and Pharmacy at Ho Chi Minh City·Preclinical·NCT07746934·600 enrolled
Regulatory
FDA Approval Timeline[4]
May 17, 2004
TINDAMAX
NDA NDA021618
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tinidazole. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMission Pharmacal